PP-LAI dominated the other atypicals. It appears to be the preferred option for treating chronic relapsing schizophrenia.

PP-LAI followed by OLZ-LAI was cost-effective in Sweden for chronic schizophrenia and cost-saving overall to the healthcare system.

PLAI was cost saving from a Swedish payer perspective compared with RLAI and OLAI in the long-term treatment of multi-episode (two or more relapses) schizophrenia patients.

PP-LAI was cost-effective compared with OLZ-LAI in treating patients with chronic schizophrenia in Norway but sensitive to changes in adherence and hospitalisation rates.

In Finland, PP-LAI dominated the other LAIs as it was associated with a lower cost and better clinical outcomes.